Clinical Trials

23 results for Kidney/Renal Cancer


A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Device: CyberKnife
  • Study ID: NCT01890590
View Trial

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

  • Condition: Papillary Renal Cell Carcinoma
  • Intervention: Drug: INC280
  • Study ID: NCT02019693
View Trial

Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

  • Condition: Metastatic Renal Cell Carcinoma (mRCC)
  • Intervention: Other: observational
  • Study ID: NCT02184416
View Trial

A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors

  • Condition: Adult Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Colorectal Carcinoma, Recurrent Melanoma, Recurrent Ovarian Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Ovarian Cancer, Stage IVA Colorectal Cancer, Stage
  • Intervention: Other: Laboratory Biomarker Analysis, Biological: Pembrolizumab, Biological: Ziv-Aflibercept
  • Study ID: NCT02298959
View Trial

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.

  • Condition: Thyroid Cancer, Medullary
  • Intervention: Drug: 177Lu-PP-F11N
  • Study ID: NCT02088645
View Trial

Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (> = 70 Years) - PHRC-K13-170

  • Condition: Cancer
  • Intervention: Drug: melatonin, Drug: placebo
  • Study ID: NCT02454855
View Trial

Hematopoietic Stem Cell Transplant for Sickle Cell Disease

  • Condition: Sickle Cell Disease, Sickle Cell Anemia, SCD
  • Intervention: Drug: Fludarabine, Procedure: Hematopoietic Stem Cell Transplant (HSCT)
  • Study ID: NCT02065596
View Trial

Kidney Cancer DNA Registry

  • Condition: Renal Cancer
  • Intervention: Other: salvia for germline DNA, Behavioral: the Kidney Cancer Questionnaire, Behavioral: Family History Questionnaire (when applicable)
  • Study ID: NCT02087852
View Trial

caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)

  • Condition: Metastatic Collecting Duct Renal Cell Carcinoma
  • Intervention: Drug: Cabometyx
  • Study ID: NCT03354884
View Trial

Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma

  • Condition: Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
  • Intervention: Drug: Cabozantinib, Drug: Sunitinib
  • Study ID: NCT03541902
View Trial

Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy

  • Condition: Renal Cell Carcinoma
  • Intervention: Other: Data collection
  • Study ID: NCT03419572
View Trial

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

  • Condition: Clear Renal Cell Cancer (< 7cm Size)
  • Intervention: Procedure: Partial or radical nephrectomy
  • Study ID: NCT03694912
View Trial

Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors

  • Condition: Renal Tumor
  • Intervention: Radiation: Stereotactic Ablative Radiotherapy
  • Study ID: NCT03747133
View Trial

Phase II Trial of AZD6738 Alone and in Combination With Olaparib in Patients With Selected Solid Tumor Malignancies

  • Condition: Clear Cell Renal Cell Carcinoma, Locally Advance Pancreatic Ductal Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Pancreatic Ductal Ad
  • Intervention: Drug: ATR Kinase Inhibitor AZD6738, Drug: Olaparib
  • Study ID: NCT03682289
View Trial

A Phase I Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1 Inhibitors

  • Condition: Oncology, Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma, Bladder Cancer
  • Intervention: Drug: MRx0518, Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
  • Study ID: NCT03637803
View Trial

A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partia

  • Condition: Kidney Cancer, Prostate Cancer
  • Intervention: Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, Drug: 0.9% Sodium Chloride Injection
  • Study ID: NCT03824808
View Trial

An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Durvalumab, Drug: Tremelimumab
  • Study ID: NCT03288532
View Trial

A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma

  • Condition: Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
  • Intervention: Biological: Aldesleukin, Biological: Pembrolizumab
  • Study ID: NCT03260504
View Trial

Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Other: Carevive software
  • Study ID: NCT03229083
View Trial

Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma

  • Condition: Kidney Cancer
  • Study ID: NCT03414827
View Trial

Phase II Clinical Study of PD-1 Monoclonal Antibody Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in the Second-line Treatment of Metastatic Clear Cell Renal Cell Carcinoma

  • Condition: Metastic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Second-line Treatment
  • Intervention: Biological: SHR-1210, Biological: CIK cells
  • Study ID: NCT03987698
View Trial

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Nivolumab, Drug: Axitinib
  • Study ID: NCT03172754
View Trial

A Phase III, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination With Cabozantinib Versus Cabozantinib Alone in Patients With Inoperable, Locally Advanced, or Metastatic Renal Cell Carcinoma W

  • Condition: Carcinoma, Renal Cell
  • Study ID: NCT04338269
View Trial